El pertuzumab de Biocon se convierte en el primer biosimilar en obtener una opinión positiva del CHMP de la EMA bajo el nuevo enfoque clínico adaptado
BENGALURU, India, 22 de septiembre de 2026 /PRNewswire/ -- Biocon Biologics Limited, filial íntegramente participada por Biocon Limited (BSE: 532523) (NSE: BIOCON), ha anunciado hoy que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha emitido...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- The Biological Computing Co. Partners with AWS to Bring World's First Neuron-Derived AI Video Model to Market
- Perforce Delphix Launches AI-Native Synthetic Data Solution
- Hollyland predstavuje LARK M3: flexibilný a škálovateľný bezdrôtový audio systém pre viacero osôb a viacero kamier
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →